Cumberland Pharmaceuticals (CPIX) Revenue & Revenue Breakdown

OverviewOwnership Financials Chart Transcripts

Cumberland Pharmaceuticals Revenue Highlights

Latest Revenue (Y)

$39.55M

Latest Revenue (Q)

$9.09M

Main Segment (Y)

Product

Main Geography (Y)

Non-US

Cumberland Pharmaceuticals Revenue by Period

Cumberland Pharmaceuticals Revenue by Year

Date	Revenue	Change
2023-12-31	$39.55M	-5.85%
2022-12-31	$42.01M	16.75%
2021-12-31	$35.99M	-3.89%
2020-12-31	$37.44M	8.88%
2019-12-31	$34.39M	-15.59%
2018-12-31	$40.74M	-0.99%
2017-12-31	$41.15M	24.60%
2016-12-31	$33.03M	-1.47%
2015-12-31	$33.52M	-9.17%
2014-12-31	$36.90M	15.22%
2013-12-31	$32.03M	-34.44%
2012-12-31	$48.85M	-4.48%
2011-12-31	$51.14M	11.48%
2010-12-31	$45.88M	5.37%
2009-12-31	$43.54M	24.13%
2008-12-31	$35.08M	24.98%
2007-12-31	$28.06M	57.52%
2006-12-31	$17.82M	66.66%
2005-12-31	$10.69M	-

Cumberland Pharmaceuticals generated $39.55M in revenue during NA 2023, up -5.85% compared to the previous quarter, and up 97.08% compared to the same period a year ago.

Cumberland Pharmaceuticals Revenue by Quarter

Date	Revenue	Change
2024-09-30	$9.09M	-7.75%
2024-06-30	$9.85M	15.90%
2024-03-31	$8.50M	-9.15%
2023-12-31	$9.35M	-7.27%
2023-09-30	$10.09M	-7.37%
2023-06-30	$10.89M	18.04%
2023-03-31	$9.22M	1.11%
2022-12-31	$9.12M	-20.06%
2022-09-30	$11.41M	10.82%
2022-06-30	$10.30M	-7.84%
2022-03-31	$11.18M	34.32%
2021-12-31	$8.32M	3.06%
2021-09-30	$8.07M	-10.85%
2021-06-30	$9.06M	-14.06%
2021-03-31	$10.54M	2.69%
2020-12-31	$10.26M	10.93%
2020-09-30	$9.25M	-3.62%
2020-06-30	$9.60M	15.21%
2020-03-31	$8.33M	-39.10%
2019-12-31	$13.68M	31.88%
2019-09-30	$10.37M	-10.44%
2019-06-30	$11.58M	-2.71%
2019-03-31	$11.90M	-11.82%
2018-12-31	$13.50M	58.94%
2018-09-30	$8.49M	-16.44%
2018-06-30	$10.16M	18.35%
2018-03-31	$8.59M	-26.28%
2017-12-31	$11.65M	4.04%
2017-09-30	$11.20M	29.19%
2017-06-30	$8.67M	-10.06%
2017-03-31	$9.64M	6.11%
2016-12-31	$9.08M	3.29%
2016-09-30	$8.79M	18.57%
2016-06-30	$7.41M	-4.17%
2016-03-31	$7.74M	-3.73%
2015-12-31	$8.04M	1.93%
2015-09-30	$7.89M	-11.50%
2015-06-30	$8.91M	2.57%
2015-03-31	$8.69M	-6.89%
2014-12-31	$9.33M	-4.11%
2014-09-30	$9.73M	-0.22%
2014-06-30	$9.75M	20.47%
2014-03-31	$8.09M	-0.81%
2013-12-31	$8.16M	24.98%
2013-09-30	$6.53M	-7.80%
2013-06-30	$7.08M	-30.97%
2013-03-31	$10.26M	-25.10%
2012-12-31	$13.70M	9.29%
2012-09-30	$12.53M	1.33%
2012-06-30	$12.37M	20.58%
2012-03-31	$10.26M	-21.30%
2011-12-31	$13.03M	-0.17%
2011-09-30	$13.05M	-9.28%
2011-06-30	$14.39M	34.90%
2011-03-31	$10.67M	-16.76%
2010-12-31	$12.81M	5.12%
2010-09-30	$12.19M	13.51%
2010-06-30	$10.74M	6.01%
2010-03-31	$10.13M	-5.45%
2009-12-31	$10.71M	-21.21%
2009-09-30	$13.60M	38.46%
2009-06-30	$9.82M	4.42%
2009-03-31	$9.40M	-4.14%
2008-12-31	$9.81M	14.05%
2008-09-30	$8.60M	2.93%
2008-06-30	$8.36M	0.65%
2008-03-31	$8.30M	11.70%
2007-12-31	$7.43M	-

Cumberland Pharmaceuticals generated $9.09M in revenue during Q3 2024, up -7.75% compared to the previous quarter, and up 83.44% compared to the same period a year ago.

Cumberland Pharmaceuticals Revenue Breakdown

Cumberland Pharmaceuticals Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Product	$37.51M	-	-	-	-
Manufactured Product, Other	$2.04M	-	-	-	-
Kristalose	-	$15.21M	$15.99M	$15.57M	$12.90M
Product, Vibativ	-	$7.49M	$11.70M	$10.87M	$8.69M
Caldolor	-	$4.83M	$4.97M	$5.34M	$5.22M
Acetadote	-	$501.04K	$850.99K	$1.87M	$3.82M
Vaprisol	-	$-447.70K	$1.86M	$1.08M	$936.62K
Sancuso	-	$13.21M	-	-	-
RediTrex	-	$-126.73K	$55.32K	$856.66K	-
Omeclamox-Pak	-	-	$-388.66K	$257.09K	$837.83K
Product, Ethyol	-	-	-	-	$12.77M
Product, Totect	-	-	-	-	$369.91K

Cumberland Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 23: Product (94.84%), and Manufactured Product, Other (5.16%).

Quarterly Revenue by Product

Product/Service	Sep 24	Mar 24	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19
Product - Vibativ	$1.03M	$1.61M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Product - Other	$624.20K	$275.33K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
VIBATIV	-	-	$2.79M	$2.15M	$1.85M	$1.91M	$1.60M	$2.50M	$325.77K	$399.95K	$1.13M	$2.81M	$3.30M	$2.43M	$1.45M	$2.60M	-	-	-	-
Acetadote	-	-	$120.05K	$150.16K	$169.86K	$163.35K	$99.79K	$126.79K	$111.09K	$212.29K	$4.01M	$5.28M	$2.99M	$347.03K	$218.46K	$595.31K	$713.90K	$1.22M	$777.18K	$983.47K
Sancuso	-	-	$1.93M	$1.92M	$1.89M	$2.45M	$3.96M	$3.40M	$3.40M	-	-	-	-	-	-	-	-	-	-	-
RediTrex	-	-	$-122.56K	$9.49K	$-141.04K	$-365.44K	$85.81K	$93.68K	$59.23K	$68.61K	$11.46K	$7.38K	$-32.25K	-	-	-	-	-	-	-
Other Products	-	-	$299.36K	$1.30M	$197.19K	$496.79K	$480.16K	$295.62K	$178.89K	$461.15K	$182.10K	$265.05K	$874.21K	$459.56K	$270.85K	$612.03K	-	-	-	-
Omeclamox-Pak	-	-	$23.29K	$8.06K	$-2.52K	$35.60K	$-26.41K	$22.74K	$63.03K	$1.90M	$1.84M	$5.05M	$-383.35K	$516.07K	$10.95K	$114.77K	$43.62K	$116.06K	$478.60K	-
Kristalose	-	-	$3.89M	$4.11M	$4.32M	$3.79M	$3.90M	$3.57M	$3.95M	$3.71M	$1.26M	$938.33K	$1.54M	$5.18M	$3.62M	$3.48M	$3.31M	$3.17M	$2.92M	$3.48M
Caldolor	-	-	$1.16M	$1.23M	$935.04K	$1.75M	$921.81K	$1.19M	$959.63K	$1.24M	$22.69K	$-24.11K	$-450.26K	$1.66M	$1.42M	$1.17M	$1.10M	$1.68M	$1.17M	$1.05M
Vaprisol	-	-	-	$23.86K	$16.01K	$-195.64K	$-436.00	$-134.62K	$-117.00K	$-1.55K	$368.73K	$152.78K	$117.19K	$286.41K	$406.16K	$174.16K	$208.76K	$212.47K	$224.94K	$212.53K
Grant	-	-	-	-	-	-	-	-	$40.00K	$20.00K	$200.00K	$100.00K	$100.00K	$100.00K	-	-	-	-	-	-
Totect	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$137.34K	$154.91K
Ethyol	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$3.30M	$2.01M

Cumberland Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Product - Vibativ (62.22%), and Product - Other (37.78%).

Cumberland Pharmaceuticals Revenue Breakdown by Country

Annual Revenue by Country

Country	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Non-US	$1.10M	$1.50M	$2.20M	$2.40M	$1.50M

Cumberland Pharmaceuticals's latest annual revenue breakdown by geography, as of Dec 23: Non-US (100.00%).

Cumberland Pharmaceuticals Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
PTPI	Petros Pharmaceuticals	$5.82B	$1.42M
IRWD	Ironwood Pharmaceuticals	$442.74M	$91.59M
ORGO	Organogenesis	$433.14M	$115.18M
PROC	Procaps Group	$409.92M	$118.41M
EGRX	Eagle Pharmaceuticals	$316.61M	$64.65M
KMDA	Kamada	$144.76M	$37.40M
LFCR	Lifecore Biomedical	$128.26M	$24.70M
ALIM	Alimera Sciences	$80.75M	$23.01M
CPIX	Cumberland Pharmaceuticals	$39.55M	$9.09M
BFRI	Biofrontera	$34.01M	$7.83M
AGRX	Agile Therapeutics	$19.59M	$5.58M
GHSI	Guardion Health Sciences	$12.25M	$36.35K
EVOK	Evoke Pharma	$5.18M	$2.65M
AKAN	Akanda	$2.16M	$762.61K
LSDI	Lucy Scientific Discovery	$7.05K	$9.68K
SHPH	Shuttle Pharmaceuticals	-	-
IXHL	Incannex Healthcare	-	$12.00K
PRFX	PainReform	-	-
RGC	Regencell Bioscience	-	-

CPIX Revenue FAQ

What is Cumberland Pharmaceuticals’s yearly revenue?

Cumberland Pharmaceuticals's yearly revenue for 2023 was $39.55M, representing a decrease of -5.85% compared to 2022. The company's yearly revenue for 2022 was $42.01M, representing an increase of 16.75% compared to 2021. CPIX's yearly revenue for 2021 was $35.99M, representing a decrease of -3.89% compared to 2020.

What is Cumberland Pharmaceuticals’s quarterly revenue?

Cumberland Pharmaceuticals's quarterly revenue for Q3 2024 was $9.09M, a -7.75% decrease from the previous quarter (Q2 2024), and a -9.92% decrease year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $9.85M, a 15.90% increase from the previous quarter (Q1 2024), and a -9.55% decrease year-over-year (Q2 2023). CPIX's quarterly revenue for Q1 2024 was $8.5M, a -9.15% decrease from the previous quarter (Q4 2023), and a -7.88% decrease year-over-year (Q1 2023).

What is Cumberland Pharmaceuticals’s revenue growth rate?

Cumberland Pharmaceuticals's revenue growth rate for the last 3 years (2021-2023) was 9.91%, and for the last 5 years (2019-2023) was 15.02%.

What are Cumberland Pharmaceuticals’s revenue streams?

Cumberland Pharmaceuticals's revenue streams in c 23 are Product, and Manufactured Product, Other. Product generated $37.51M in revenue, accounting 94.84% of the company's total revenue Manufactured Product, Other generated $2.04M in revenue, accounting 5.16% of the company's total revenue

What is Cumberland Pharmaceuticals’s main source of revenue?

For the fiscal year ending Dec 23, the largest source of revenue of Cumberland Pharmaceuticals was Product. This segment made a revenue of $37.51M, representing 94.84% of the company's total revenue.